Hepatectomy for liver metastases from squamous cell laryngeal cancer. Is it worthy?

• Autorzy: Alexander Julianov , Maya Gulubova
• Języki publikacji: EN

Abstrakty

EN

Patients with liver metastases from squamous cell head and neck cancer (SCHNC) are usually treated with chemotherapy and are not evaluated for eventual liver-directed treatment. However, the potential benefits from liver surgery for the patients with hepatic-only metastases from SCHNC generally remain undefined. We report a patient with late liver-only metastases from squamous cell glottic cancer treated with resection of the liver metastases followed by adjuvant platinum-based chemotherapy plus cetuximab. The patient died 25 months after resection of the hepatic metastases from widespread hepatic and pulmonary recurrence. The literature data as well as this case demonstrates the capability of liver surgery to prolong survival in patients with hepatic metastases from SCHNC.

Słowa kluczowe

EN

Head and neck cancer; Liver metastases; Liver resection

• Czasopismo: Open Medicine
• Rocznik: 2010
• Tom: 5
• Numer: 5
• Strony: 535-537

Daty

wydano

2010-10-01

online

2010-08-20

Twórcy

autor

Alexander Julianov

• Department of General Surgery, Thracian University Hospital, 6000, Stara Zagora, Bulgaria,

autor

Maya Gulubova

• Department of Pathology, Thracian University Hospital, 6000, Stara Zagora, Bulgaria

Bibliografia

• [1] Forastiere A.A., Metch B., Schuller D.E., Ensley J.F., Hutchins L.F., Triozzi P., et al., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol, 1992, 10, 1245–1251
• [2] Jacobs C., Lyman G., Velez-Garcia E., Sridhar K.S., Knight W., Hochster H., et al., A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol, 1992, 10, 257–263 [PubMed]
• [3] Clavel M., Vermorken J.B., Cognetti F., Cappelaere P., de Mulder P.H., Schornagel J.H., et al., Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol, 1994, 5, 521–526
• [4] Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008, 359, 1116–1127 http://dx.doi.org/10.1056/NEJMoa0802656[WoS][Crossref]
• [5] Choti M.A., Sitzmann J.V., Tiburi M.F., Sumethotimetha W., Rangsin R., Schulick R.D., et al., Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg, 2002, 235, 759–766 http://dx.doi.org/10.1097/00000658-200206000-00002[Crossref]
• [6] Grazi G.L., Cescon M., Pierangeli F., Ercolani G., Gardini A., Cavallarii A., et al., Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology, 2000, 47, 481–486
• [7] Lendoire J., Moro M., Andriani O., Grondona J., Gil O., Raffin G., et al., Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina. HPB, 2007, 9, 435–439 http://dx.doi.org/10.1080/13651820701769701[Crossref]
• [8] Weitz J., Blumgart L.H., Fong Y., Jarnagin W.R., D’Angelica M., Harrison L.E., et al., Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg, 2005, 241, 269–276 http://dx.doi.org/10.1097/01.sla.0000150244.72285.ad[Crossref]
• [9] Ercolani G., Grazi G.L., Ravaioli M., Ramacciato G., Cescon M., Varotti G., et al., The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol, 2005, 12, 1–8 http://dx.doi.org/10.1245/ASO.2005.06.034[Crossref]
• [10] Elias D., Cavalcanti de Albuquerque A., Eggenspieler P., Eggenspieler P., Plaud B., Ducreux M., et al., Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg, 1998, 187, 487–493 http://dx.doi.org/10.1016/S1072-7515(98)00225-7[Crossref]
• [11] Adam R., Chiche L., Aloia T., Elias D., Salmon R., Rivoire M., et al., Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg, 2006, 244, 524–535 http://dx.doi.org/10.1097/01.sla.0000246847.02058.1b[Crossref]
• [12] Pawlik T.M., Gleisner A.L., Bauer T.W., Adams R.B., Reddy S.K., Clary B.M., et al., Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol, 2007, 14, 2807–2816 http://dx.doi.org/10.1245/s10434-007-9467-8[Crossref]

Identyfikatory

DOI

10.2478/s11536-010-0035-4